Keywords: Santarus, Covella, M&A, Biogen Idec, Inflammatory, Autoimmune diseases

Santarus gets rights to inflammatory/autoimmune disease candidate by buying Covella

Article | 15 September 2010

Print This

In what has been a busy acquisitive week for the US specialty biopharma firm, Santarus (Nasdaq: SNTS) has acquired the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in